Emilia Solinas

Dr. Emilia Solinas

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in European Heart Journal Supplements
Verified
Journal Article
Open access
PDF file
Filippo Luca GurgoglioneFilippo Luca Gurgoglione
Filippo Luca Gurgoglione
MCM Cattabiani
M Cattabiani
LVL Vignali
L Vignali
Emilia SolinasEmilia Solinas
Emilia Solinas
CDC Dizdari
C Dizdari
GNGiampaolo Niccoli
Giampaolo Niccoli
Transcatheter patent foramen ovale (PFO) closure has been shown to lower recurrent stroke in patients with cryptogenic stroke (CS) or transient ischemic attack (TIA) with an indication for closure. However, the incidence of recurrent stroke is not negligible and underlying pathogenic mechanisms remain largely unknown. We sought to evaluate the prevalence of recurrent CS/TIA and to assess its predictors after transcatheter PFO closure. We enrolled consecutive patients who underwent PFO closure for secondary prevention of neurological ischemic events at the University Hospital of Parma between 2006 and 2021. For each subject, CS/TIA index event was diagnosed after exclusion of alternative etiologies, PFO features were characterized by transesophageal echocardiography (TEE), the Risk of Paradoxical Embolism (ROPE) score was retrospectively assessed and the presence of migraine was investigated. Clinical follow–up was scheduled with outpatient visits at 3 – 12 months and yearly thereafter device implantation; the primary outcome was the recurrence of any ischemic neurological event. We enrolled a total of 169 patients with mean Risk of Paradoxical Embolism (ROPE) score at hospital admission of 6.4 ± 1.5. The primary indication for PFO closure was previous CS (94 [55.6%] subjects), followed by TIA (75 [44.4%]). Among patients with complete outcome data (n= 154), after a median follow–up of 112 months, recurrent cerebral ischemia occurred in 13 [8.4%], with an annualized rate of 0.92/100 patients. The presence of obesity [OR 5.268, p = 0.018], ROPE score < 7 [OR 5.991, p = 0.035] and migraine [OR = 5.932 p = 0.012] were independent positive predictors of recurrent stroke/TIA after PFO closure. In our study, recurrent cerebral events after PFO closure were not negligible, with an annualized rate of 0.92/100 patients, consistent with prior research. Multiple heterogeneous predictors were identified: the presence of obesity, ROPE score < 7 and migraine were independent positive predictors of recurrent stroke/TIA after PFO closure

20 June 2023 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
GPGiovanna Pelà
Giovanna Pelà
Francesco VisioliFrancesco Visioli
Francesco Visioli
Marina AielloMarina Aiello
Marina Aiello
Emilia SolinasEmilia Solinas
Emilia Solinas
CFC Ferrari
C Ferrari
Alfredo ChettaAlfredo Chetta
Alfredo Chetta

Verified
Journal Article
Open access
PDF file
MGMattia De Gregorio
Mattia De Gregorio
Andrea DenegriAndrea Denegri
Andrea Denegri
Filippo Luca GurgoglioneFilippo Luca Gurgoglione
Filippo Luca Gurgoglione
GBGiorgio Benatti
Giorgio Benatti
ITIacopo Tadonio
Iacopo Tadonio
GNGiampaolo Niccoli
Giampaolo Niccoli
Antithrombotic therapy plays a pivotal role in reducing thromboembolic complications, including stroke and valve thrombosis, following Transcatheter Aortic Valve Implantation (TAVI). However, the benefits of such therapy must be balanced against the increased risk of major bleeding events. The optimal antithrombotic strategy in this setting remains a matter of ongoing debate, given the heterogeneity of patient profiles and procedural variables. Among TAVI recipients, women represent a growing proportion and exhibit distinct anatomical, physiological, and clinical characteristics that influence both thrombotic and bleeding risk. Compared to men, women more frequently experience vascular complications and major bleeding events, despite better survival outcomes. These differences are driven by smaller vessel caliber, higher vascular tortuosity, and altered platelet reactivity. Consequently, sex-specific risk stratification is essential when considering antiplatelet or anticoagulant regimens post-TAVI. This review provides a comprehensive synthesis of current evidence regarding antithrombotic strategies in the post-TAVI setting, with a dedicated focus on sex-related differences. Particular emphasis is placed on the female population, assessing ischemic and hemorrhagic outcomes and the implications for long-term management. Improving outcomes in women undergoing TAVI necessitates tailored antithrombotic strategies that balance efficacy and safety. Ongoing research and dedicated trials are essential to refine these strategies and to inform future guideline updates in this expanding patient population.